MARK SCHAAF: Open Payments
NPI 1306932611 · MOUNT MORRIS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$999 in 52 payments from 17 companies in 2025. Trend: 2023 $305 · 2024 $626 · 2025 $999
Food & beverage: $999
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $267 |
| ABBVIE INC. | 14 | $147 |
| Otsuka America Pharmaceutical, Inc. | 3 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $82 |
| Novo Nordisk Inc | 4 | $62 |
| Corcept Therapeutics | 2 | $58 |
| Viatris Specialty LLC | 2 | $46 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Lilly USA, LLC | 2 | $34 |
| Abbott Laboratories | 1 | $29 |
Products named: BREZTRI, REXULTI, CAPLYTA, AIRSUPRA, VRAYLAR, UBRELVY, FARXIGA, Korlym.
Industry payments across MI — which companies pay providers there.
